SeqLL Announces Publication of a New Blood-Based RNA Sequencing Method to Detect Coronary Artery Disease WOBURN, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the...

SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL’s tSMS® Platform Method developed by leading researchers at the Bernstein Laboratory and SeqLL Inc. Funding for the research and method development provided by the National Institutes of Health (NIH) WOBURN, Mass.,...